Stockscreener 앱 받기
216.49
2.20%
4.53
전일 마감가:
$211.96
열려 있는:
$212.37
하루 거래량:
3.88M
Relative Volume:
0.73
시가총액:
$382.72B
수익:
$59.64B
순이익/손실:
$2.37B
주가수익비율:
162.65
EPS:
1.331
순현금흐름:
$18.24B
1주 성능:
-4.80%
1개월 성능:
-7.39%
6개월 성능:
+9.15%
1년 성능:
+8.06%
1일 변동 폭
$212.37
$217.08
1주일 범위
$211.69
$229.65
52주 변동 폭
$163.81
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
216.65 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
LLY
Lilly Eli Co
|
907.39 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.88 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
125.16 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.97 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Inc. SEC 10-Q Report - TradingView
AbbVie (ABBV) Receives a Buy from BMO Capital - The Globe and Mail
Schwab U.S. Dividend Equity ETF (SCHD) Offers Higher Yield and Lower Fees Than ProShares S&P 500 Dividend Aristocrats ETF (NOBL) - The Motley Fool
Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain ShiftsGlobal Forecast to 2034 - Yahoo Finance
Bernstein raises AbbVie stock price target to $225 on long-term growth - Investing.com Nigeria
Bernstein Adjusts Price Target on AbbVie to $225 From $203, Maintains Market Perform Rating - MarketScreener
AbbVie (NYSE:ABBV) Downgraded to "Hold" Rating by DZ Bank - MarketBeat
AbbVie Inc. (NYSE:ABBV) Q3 2025 Earnings Call Transcript - Insider Monkey
Here Are Tuesday's Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More - 24/7 Wall St.
Tufton Capital Management Has $10.25 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Magnolia Capital Advisors LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
Huntington National Bank Has $125.30 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
EPG Wealth Management LLC Sells 2,439 Shares of AbbVie Inc. $ABBV - MarketBeat
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominance2025 Pullback Review & Fast Entry High Yield Stock Tips - newser.com
Colorado Judge Denies AbbVie's Bid To Block State Drug Law - Law360
AbbVie (NYSE:ABBV) Stock Price Down 2.8%Here's Why - MarketBeat
Citigroup Lowers Price Target for AbbVie (ABBV) to $235 Amidst N - GuruFocus
AbbVie, Novartis Win Block of Oklahoma Drug Discount Law - Bloomberg Law News
The AbbVie Decision and the Economics of Corporate Control Markets - The National Law Review
Do Wall Street Analysts Like AbbVie Stock? - Barchart.com
JP Morgan Raises Price Target on AbbVie (ABBV) to $260, Maintains Overweight Rating | ABBV Stock News - GuruFocus
What Wall Street predicts for AbbVie Inc. stock pricePortfolio Gains Summary & Technical Confirmation Trade Alerts - newser.com
ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure - TradingView
Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio - Insider Monkey
Goldman Sachs Adjusts Price Target on AbbVie to $223 From $218 - MarketScreener
Analyst on AbbVie (ABBV): ‘Stay Long’ - Insider Monkey
Obermeyer Wealth Partners Sells 12,006 Shares of AbbVie Inc. $ABBV - MarketBeat
Bank of New York Mellon Corp Cuts Position in AbbVie Inc. $ABBV - MarketBeat
Street View: Immunology strength holds at AbbVie despite aesthetics drag - TradingView
AbbVie Inc. $ABBV Shares Acquired by Machina Capital S.A.S. - MarketBeat
AbbVie Inc. $ABBV Holdings Lifted by Tsfg LLC - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Bank of Montreal Can - MarketBeat
Raymond James raises Abbvie stock price target to $256 on solid growth - Investing.com Nigeria
AbbVie Inc. $ABBV Shares Sold by Texas Bank & Trust Co - MarketBeat
Torray Investment Partners LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Raymond James Adjusts Price Target on AbbVie to $256 From $250, Maintains Outperform Rating - MarketScreener
JPMorgan Adjusts Price Target on AbbVie to $260 From $250, Maintains Overweight Rating - MarketScreener
BNP Paribas Exane Adjusts Price Target on AbbVie to $203 From $197, Maintains Neutral Rating - MarketScreener
Burney Co. Has $11.59 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock undervalued at current priceGap Up & High Accuracy Investment Entry Signals - newser.com
Sigma Planning Corp Sells 4,396 Shares of AbbVie Inc. $ABBV - MarketBeat
United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key PlayersNovartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb - GlobeNewswire
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Market Risk Analysis & High Return Stock Watch Alerts - newser.com
Targeted Drug Delivery Market Set to Witness Massive Growth - openPR.com
Can AbbVie Inc. stock retain market dominanceJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Will AbbVie Inc. stock beat EPS estimatesProduct Launch & Real-Time Stock Movement Alerts - newser.com
Why AbbVie Inc. (4AB) stock stays on top picks2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
How to recover losses in AbbVie Inc. stockWeekly Profit Analysis & Stock Portfolio Risk Management - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Stock Summary & Capital Efficient Trading Techniques - newser.com
Reversal indicators forming on AbbVie Inc. stockEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
2.05%
자본화:
|
볼륨(24시간):